LeMaitre Vascular, Inc. LMAT
At closeNov 6, 2026, 7:04 AM EST
Pre-market · Nov 6, 7:04 AM ET
- YTD
- +2.95%
- 1 year
- -3.22%
- Market cap
- 1.91B
- Revenue (ttm)
- 262.43M
- Profit margin
- 25.02%
- EPS (ttm)
- 2.75
- Shares out
- 22.87M
- P/E ratio
- 30.36
- Forward P/E
- 27.66
- Dividend
- 1.00 (1.24%)
- Ex-dividend date
- Aug 19, 2026
- YTD return
- +2.95%
- 1-year return
- -3.22%
- Volume
- 533.76K
- Avg volume
- 300.44K
- Open
- 81.79
- Previous close
- 87.92
- Day's range
- 80.73 – 85.97
- 52-week range
- 78.22 – 118.01
- Beta
- 0.49
- Analysts
- Buy
- Price target
- 107.00 (+28.2%)
- Earnings date
- Feb 24, 2027
5D -1.33 (-1.57%)
Key statistics
- Enterprise value
- 1.66B
- PEG ratio
- 2.13
- Price / sales
- 7.66
- Price / book
- 4.78
- Dividend yield
- 1.24%
- Payout ratio
- 31.58%
- Revenue growth
- 9.60%
- Free cash flow
- 49.26M
- Total cash
- 376.24M
- Total debt
- 190.25M
- Return on equity
- 16.77%
- Short % of float
- 9.76%
- 50-day average
- 81.20
- 200-day average
- 94.40
Analyst view
Consensus: buy
- Target (low)
- 81.00
- Target (mean)
- 107.00
- Target (high)
- 132.00
- Strong buy2
- Buy2
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 0.68625.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | 0.78 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.686 | 0.65 | -0.04 | -5.25% |
| Aug 4, 2026 | Jun 30, 2026 | 0.807 | 0.74 | -0.07 | -8.30% |
| May 5, 2026 | Mar 31, 2026 | 0.66 | 0.68 | +0.02 | +3.03% |
| Feb 25, 2026 | Dec 31, 2025 | 0.67 | 0.68 | +0.01 | +1.49% |
| Nov 6, 2025 | Sep 30, 2025 | 0.564 | 0.62 | +0.06 | +9.93% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 5, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Jun 3, 2026 | Barrington Research | main | Outperform | Outperform |
| May 6, 2026 | Barrington Research | main | Outperform | Outperform |
| May 6, 2026 | Citizens | main | Market Outperform | Market Outperform |
| May 6, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Feb 26, 2026 | Barrington Research | main | Outperform | Outperform |
About LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- lemaitre.com
News
Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Lowers Price Target to $86
Citizens Maintains Market Outperform on LeMaitre Vascular, Lowers Price Target to $110
LeMaitre Vascular Q3 Earnings Call Highlights
LeMaitre Vascular (LMAT) Misses Q3 Earnings Estimates
LeMaitre Vascular Q3 2026 Earnings Call Transcript LeMaitre Vascular Lowers FY2026 GAAP EPS Guidance from $2.84-$2.94 to $2.77-$2.82 vs $2.87 Est; Narrows FY2026 Sales Guidance from $274.300M-$278.300M to $274.800M-$276.800M vs $276.539M Est
LeMaitre Vascular Lowers Q4 GAAP EPS Guidance from $0.75-$0.81 to $0.70-$0.75 vs $0.78 Est; Lowers Q4 Sales Guidance from $71.100M-$73.100M to $69.900M-$71.900M vs $72.325M Est
LeMaitre Q3 2026 Financial Results
Dividend Income Report: +15.25% And A Listener's Portfolio Roast L3Harris Technologies Receives 7-Year, $4.7B Lockheed Martin Contract To Produce Propulsion Systems For PAC-3 Missile Segment Enhancement Interceptor
Your note
Sign in to keep a note on LMAT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JASINSKI LAWRENCE J | Director | Sale | May 6, 2026 | 4,714 |
| KAMKE TRENT G | Officer | Sale | Mar 10, 2026 | 6,677 |
| LEBLANC DORIAN PAUL CPA | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 9, 2026 | 2,302 |
| LEMAITRE GEORGE W | Chief Executive Officer | Stock Award(Grant) | Jun 3, 2026 | 0 |
| O'CONNOR JOHN JAMES EDWARD | Director | Stock Award(Grant) | Feb 25, 2026 | 62,827 |
| PELLEGRINO JOSEPH P JR | Director | Conversion of Exercise of derivative security | Apr 21, 2026 | 15,021 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 14.31% | 3,272,973 | 287.76M | Jun 29, 2026 |
| First Trust Advisors LP | 4.78% | 1,093,502 | 96.14M | Jun 29, 2026 |
| Congress Asset Management Co | 4.20% | 961,514 | 84.54M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.17% | 953,437 | 83.83M | Jun 29, 2026 |
| Copeland Capital Management, LLC | 4.04% | 924,081 | 81.25M | Sep 29, 2026 |
| State Street Corporation | 3.94% | 901,416 | 79.25M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.53% | 1,265,638 | 111.27M | Sep 29, 2026 |
| First TRT Exch-Trd Fd. VI-First TRT SMID Cap Rising Dividend Achievers | 4.64% | 1,061,703 | 93.34M | Sep 29, 2026 |
| Conestoga Funds-Conestoga Small Cap Fund | 3.80% | 869,016 | 76.40M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.02% | 690,806 | 60.74M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.46% | 563,062 | 49.50M | Sep 29, 2026 |
| Professionally Managed Portfolios-Congress Small Cap Growth Fund | 2.06% | 470,000 | 41.32M | Sep 29, 2026 |
